AMG 420 Continues to Show Efficacy in Relapsed/Refractory Myeloma
In updated results from the first-in-human study of the bispecific T-cell engager (BITE) AMG 420, the agent continued to demonstrate clinical activity in patients...
Equal Access to Treatment Erases Difference in Outcomes Between White and African American Patients...
If African American patients with multiple myeloma (MM) are given equal access to treatments, they have outcomes that are as good as or better...
Daratumumab Combination Extends Progression-Free Survival for Transplant-Ineligible Myeloma
In patients with newly diagnosed multiple myeloma (MM) who were ineligible for autologous hematopoietic cell transplantation (AHCT), adding daratumumab to a regimen of lenalidomide...
FDA Grants Selinexor Accelerated Approval Despite Concerns With Trial Data
The U.S. Food and Drug Administration (FDA) granted accelerated approval to for selinexor, an oral selective inhibitor of nuclear export (SINE), for patients with...
FDA Lifts Partial Clinical Hold on Venetoclax Trial in Myeloma
Researchers can move forward with the phase III CANOVA trial, now that the U.S. Food and Drug Administration (FDA) has lifted a partial clinical...
FDA Approves Daratumumab for Patients with Transplant-Ineligible Myeloma
On June 27, 2019, the U.S. Food and Drug Administration (FDA) approved daratumumab, in combination with lenalidomide and dexamethasone, for patients with newly diagnosed...
Paul Richardson: Isatuximab Improves PFS in Relapsed/Refractory Myeloma
Paul Richardson, MD, shares results seen with isatuximab in heavily refractory myeloma, and discusses how this new agent compares with approved monoclonal antibodies.
New Subcutaneous Daratumumab Formulation Overcomes Infusion Barrier for Patients
Daratumumab-based regimens have shown efficacy across all lines of therapy in multiple myeloma (MM), but the agent requires a long intravenous infusion time, lasting...
Iberdomide: A New Immunomodulatory Drug for Heavily Refractory Myeloma
One-third of patients with relapsed/refractory multiple myeloma (MM) responded to treatment with the investigational agent iberdomide, according to early results from a first-in-human trial. Sagar...
Isatuximab Combo Improves Progression-Free Survival in Pretreated Myeloma
In an update from the phase III ICARIA-MM trial, researchers reported that the combination of the anti-CD38 monoclonal antibody isatuximab with pomalidomide and dexamethasone...
Current Issue
August 2019, Volume 5, Issue 10
This issue features a debate about gun control as a health care issue, a look at blood services in Israel and Palestine, and more.
